Regulation of basal myocardial function by NO

Cardiovascular Research

Volumn 41, Issue 3, 1999, Pages 514-523

  Kojda, Georg ^a   Kottenberg, Karin ^a  

^a Institut fur Pharmakologie und Klinische Pharmakologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIC GMP; CYTOKINE; HEART ENZYME; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE;

CHRONOTROPISM; ENZYME INDUCTION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CYCLIC GMP; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 0033061853     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00314-9     Document Type: Review

References (100)

1. Ahlner J., Andersson R.G.G., Torfgård K., Axelsson K.L. Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol Rev. 43:1991;351-423.
2. Moncada S., Palmer R.M.J., Higgs A. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension. 12:1988;365-372.
3. Nathan C., Xie Q. Nitric oxide synthases: Roles, tolls, and controls. Cell. 78:1994;915-918.
4. Moncada S., Higgs A. Mechanisms of disease: The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
5. Wilson R.I., Yanovsky J., Gödecke A.et al. Endothelial nitric oxide synthase and LTP. Nature. 386:1997;338.
6. Snyder S.H., Bredt D.S. Nitric oxide as a neuronal messenger. Trends Pharmacol Sci. 12:1991;125-128.
7. Mayer B., Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci. 22:1997;477-481.
8. Bhagat K., Vallance P. Inducible nitric oxide synthase in the cardiovascular system. Br Heart J. 75:1996;218-220.
9. Nathan C. Inducible nitric oxide synthase: What difference does it make? J Clin Invest. 100:1997;2417-2423.
10. Kelly R.A., Balligand J.L., Smith T.W. Nitric oxide and cardiac function. Circ Res. 79:1996;363-380.
11. Balligand J.-L., Cannon P.J. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol. 17:1997;1846-1858.
12. Murrel W. Nitro-glycerine as a remedy for angina pectoris. Lancet. 1:1879;80-81.
13. Chung S.-J., Fung H.-L. A common enzyme may be responsible for the conversion of organic nitrates to nitric oxide in vascular microsomes. Biochem Biophys Res Commun. 185:1992;932-937.
14. Kowaluk E.A., Seth P., Fung H.-L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther. 262:1992;916-922.
15. Hall V.A., Guest J.M. Sodium nitroprusside induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. Am J Crit Care. 1:1992;19-25.
16. Dawson R., Felheim R., Nguyen S. Mechanism of sodium nitroprusside-mediated inhibition of aromatic amino acid decarboxylase activity. Pharmacology. 50:1995;74-85.
17. Feelisch M., Ostrowski J., Noack E. On the mechanism of NO-release from sydnonimines. J Cardiovasc Pharmacol. 14(suppl. 11):1989;S13-S22.
18. Feelisch M. The biochemical pathways of nitric oxide formation from nitrovasodilators: Appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol. 17(Suppl. 3):1991;S25-S33.
19. ×: A pulse radiolysis study. Free Radic Biol Med. 19:1995;505-510.
20. + as the effective reagent in NO-formation from s-nitrosothiols (RSNO). J Chem Soc. Perkin Trans. 2:1996;481-487.
21. Barnett D.J., McAninly J., Williams D.L.H. Transnitrosation between nitrosothiols and thiols. J Chem Soc Perkin Trans. 2:1994;1131-1133.
22. De Belder A., Lees C., Martin J., Moncada S., Campbell S. Treatment of HELLP syndrome with nitric oxide donor. Lancet. 345:1995;124-125.
23. Keefer L.K., Nims R.W., Davies K.M., Wink D.A. 'NONOates' (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol. 268:1996;281-293.
24. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., Cohen R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 368:1994;850-853.
25. Xie Y.W., Shen W.Q., Zhao G.et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro - Implications for the development of heart failure. Circ Res. 79:1996;381-387.
26. Mittal CK, Murad F. Guanylate cyclase: Regulation of cyclic GMP metabolism. In: Nathanson JA, Kebabian JW, editors. Cyclic nucleotides I. Berlin, Heidelberg, New York: Springer, 1982:225-260.
27. Lohmann S.M., Fischmeister R., Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol. 86:1991;503-514.
28. Kirstein M., Rivet-Bastide M., Hatem S.et al. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest. 95:1995;794-802.
29. Hobbs A.J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci. 18:1997;484-491.
30. 2+-current in single heart cells. Nature. 323:1986;273-275.
31. Levi R.C., Alloatti G., Fischmeister R. Cyclic GMP regulates the Ca-channel current in guinea pig ventricular myocytes. Pflug Arch Eur J Physiol. 413:1989;685-687.
32. 2+ current is regulated by cGMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA. 88:1991;1197-1201.
33. 2+ current in guinea-pig ventricular cells. J Physiol (Lond). 443:1991;387-404.
34. Nawrath H. Does cGMP mediate the negative inotropic effect of acetylcholine in the heart? Nature. 267:1977;72-74.
35. Jahn H., Nastainnczyk W., Röhrkasten A., Schneider T., Hofman F. Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. Eur J Biochem. 178:1988;535-542.
36. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 268:1993;26286-26295.
37. 2+ in intact cardiac myocytes. Circ Res. 74:1994;970-978.
38. 2+: A story with a complex past and a promising future. Trends Pharmacol Sci. 18:1997;266-269.
39. Weisshaar R.E., Kobylarz-Singer D.C., Kaplan H.R. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J Mol Cell Cardiol. 19:1987;1025-1036.
40. Kojda G., Kottenberg K., Nix P.et al. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res. 78:1996;91-101.
41. Butt E., Nolte C., Schulz S.et al. Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP. Biochem Pharmacol. 43:1992;2591-2600.
42. 2+ channels by S-nitrosothiol nitric oxide donors. Circ Res. 81:1997;742-752.
43. Raff W.K., Drechsel U., Scholtholt J., Lochner W. Herzwirkung des Nitroglycerins. Pflug Arch Eur J Physiol. 317:1970;336-343.
44. Strauer B.E. Evidence for a positive inotropic effect of nitroglycerol on isolated human ventricular myocardium. Pharmacol Res Commun. 3:1971;377-383.
45. Diamond J., Ten Eick R.E., Trapani A.J. Are increases in cyclic GMP levels responsible for the negative inotropic effects of acetylcholine in the heart? Biochem Biophys Res Commun. 79:1977;912-918.
46. Brady A.J.B., Warren J.B., Poole-Wilson P.A., Williams T.J., Harding S.E. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol Heart Circ Physiol. 265:1993;H176-H182.
47. Mohan P., Brutsaert D.L., Paulus W.J., Sys S.U. Myocardial contractile response to nitric oxide and cGMP. Circulation. 93:1996;1223-1229.
48. Kojda G., Kottenberg K., Noack E. Inhibition of NO-synthase and soluble guanylate cyclase induces cardiodepressive effects in normal rat hearts. Eur J Pharmacol. 334:1997;181-190.
49. Ishibashi T., Hamaguchi M., Kato K.et al. Relationship between myoglobin contents and increases in cyclic GMP produced by glyceryl trinitrate and nitric oxide in rabbit aorta, right atrium and papillary muscle. Naunyn-Schmiedeberg's Arch Pharmacol. 347:1993;553-561.
50. Flesch M., Kilter H., Cremers B.et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther. 281:1997;1340-1349.
51. Preckel B., Kojda G., Schlack W.et al. Inotropic effects of glyceryl trinitrate and spontaneous NO-donors in the dog heart. Circulation. 96:1997;2675-2682.
52. Strauer B.E., Scherpe A. Ventricular function and coronary hemodynamics after intravenous nitroglycerin in coronary artery disease. Am Heart J. 95:1978;210-219.
53. Hood W.P., Amende I., Simon R., Lichtlen P.R. The effects of intracoronary nitroglycerin on left ventricular systolic and diastolic function in man. Circulation. 61:1980;1098-1104.
54. Smith J.A., Shah A.M., Lewis M.J. Factors released from endocardium of the ferret and pig modulate myocardial contraction. J Physiol (Lond). 439:1991;1-14.
55. Grocott-Mason R., Fort S., Lewis M.J., Shah A.M. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol Heart Circ Physiol. 266:1994;H1699-H1705.
56. Kojda G., Kottenberg K., Stasch J.P., Schrör K., Noack E. Positive inotropic effect of exogenous and endogenous NO in hypertrophic rat hearts. Br J Pharmacol. 122:1997;813-820.
57. Paulus W.J., Vantrimpont P.J., Shah A.J. Acute effects of nitric oxide on the left ventricular relaxation and diastolic distensibility in humans. Circulation. 89:1994;2070-2078.
58. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 105:1992;575-580.
59. Brady A.J.B., Poole-Wilson P.A., Harding S.E., Warren J.B. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol Heart Circ Physiol. 263:1992;H1963-H1966.
60. Balligand J.-L., Ungureanu-Longrois D., Simmons W.W.et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem. 269:1994;27580-27588.
61. Balligand J.-L., Kobzik L., Han X.et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem. 270:1995;14582-14586.
62. Kanai A.J., Mesaros S., Finkel M.S.et al. β-Adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol Cell Physiol. 273:1997;C1371-C1377.
63. Kitakaze M., Node K., Komamura K.et al. Evidence for nitric oxide generation in the cardiomyocytes: its augmentation by hypoxia. J Mol Cell Cardiol. 27:1995;2149-2154.
64. Balligand J.-L., Ungureanu D., Kelly R.A.et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 91:1993;2314-2319.
65. G-Methyl-L-arginine decreases contractility, cGMP and cAMP in isoproterenol-stimulated rat hearts in vitro. Eur J Pharmacol. 223:1992;1-7.
66. G-nitro-L-arginine methyl ester or indomethacin on differential regional and cardiac haemodynamic actions of arginine vasopressin and lysine vasopressin in conscious rats. Br J Pharmacol. 102:1991;65-72.
67. Klabunde R.E., Ritger R.C., Helgren M.C. Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogs. Eur J Pharmacol. 199:1991;51-59.
68. G-methyl-L-arginine in chronically instrumented conscious dogs. J Appl Physiol. 77:1994;471-475.
69. Zappellini A., Moreno H. Jr., Antunes E., De Nucci G. Dissociation between the increase in systemic vascular resistance induced by acute nitric oxide synthesis inhibition and the decrease in cardiac output in anesthetized dogs. J Cardiovasc Pharmacol. 29:1997;45-48.
70. Garthwaite J., Southam E., Boulton C.L.et al. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 48:1995;184-188.
71. Stamler J.S., Loh E., Roddy M.-A., Currie K.E., Creager M.A. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 89:1994;2035-2040.
72. Finkel M.S., Oddis C.V., Mayer O.H., Hattler B.G., Simmons R.L. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship. J Pharmacol Exp Ther. 272:1995;945-952.
73. Kaye D.M., Wiviott S.D., Balligand J.L.et al. Frequency-dependent activation of a constitutive nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes. Circ Res. 78:1996;217-224.
74. Hare J.M., Keaney J.F. Jr., Balligand J.-L.et al. Role of nitric oxide in parasympathetic modulation of β-adrenergic myocardial contractility in normal dogs. J Clin Invest. 95:1995;360-366.
75. Schulz R., Panas D.L., Catena R.et al. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α Br J Pharmacol. 114:1995;27-34.
76. Stein B., Frank P., Schmitz W., Scholz H., Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol. 28:1996;1631-1639.
77. Pinsky D.J., Cai B., Yang X.et al. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β J Clin Invest. 95:1995;677-685.
78. Finkel M.S., Oddis C.V., Jacob T.D.et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
79. Decking U.K.M., Flesche C.W., Gödecke A., Schrader J. Endotoxin-induced contractile dysfunction in guinea pig hearts is not mediated by nitric oxide. Am J Physiol Heart Circ Physiol. 268:1995;H2460-H2465.
80. Kelly R.A., Smith T.W. Cytokines and cardiac contractile function. Circulation. 95:1997;778-781.
81. Paulus W.J., Kästner S., Pujadas P.et al. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. Circulation. 96:1997;3436-3442.
82. De Belder A.J., Radomski M.W., Why H.J.F.et al. Nitric oxide synthase activities in human myocardium. Lancet. 341:1993;84-85.
83. De Belder A.J., Radomski M.W., Why H.J.et al. Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease. Br Heart J. 74:1995;426-430.
84. Satoh M., Nakamura M., Tamura G.et al. Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol. 29:1997;716-724.
85. Haywood G.A., Tsao P.S., Von der Leyen H.E.et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 93:1996;1087-1094.
86. Thoenes M., Förstermann U., Tracey W.R.et al. Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol. 28:1996;165-169.
87. Smith C.J., Huang R., Sun D.et al. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation. 96:1997;3116-3123.
88. Grocott-Mason R., Anning P., Evans H., Lewis M.J., Shah A.M. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol Heart Circ Physiol. 267:1994;H1804-H1813.
89. Bartunek J., Shah A.M., Vanderheyden M., Paulus W.J. Dobutamine enhances cardiodepressant effects of receptor-mediated coronary endothelial stimulation. Circulation. 95:1997;90-96.
90. Krause E.G., Halle W., Wollenberger A. Effect of dibutyryl cyclic GMP on cultured beating rat heart cells. Adv Cyclic Nucleotide Res. 1:1972;301-305.
91. Balligand J.-L., Kelly R.A., Marsden P.A., Smith T.W., Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 90:1993;347-351.
92. Kennedy R.H., Hicks K.K., Brian J.E. Jr., Seifen E. Nitric oxide has no chronotropic effect in right atria isolated from rat heart. Eur J Pharmacol. 255:1994;149-156.
93. Pabla R., Curtis M.J. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res. 77:1995;984-992.
94. Levine T.B., Olivari M.T., Cohn J.N. Effects of orthotopic heart transplantation on sympathetic control mechanisms in congestive heart failure. Am J Cardiol. 58:1986;1035-1040.
95. De Marco T., Dae M., Yuen-Green M.S.F.et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol. 25:1995;927-931.
96. f. Circ Res. 81:1997;60-68.
97. Shesely E.G., Maeda N., Kim H.S.et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 93:1996;13176-13181.
98. Krege J.H., Hodgin J.B., Hagaman J.R., Smithies O. A noninvasive computerized tail cuff system for measuring blood pressure in mice. Hypertension. 25:1995;1111-1115.
99. Kojda G., Laursen J.B., Ramasamy S.et al. Disruption of the eNOS-gene causes hypersensitivity of mouse aorta to vasoconstrictors and glyceryl trinitrate. Naunyn-Schmiedeberg's Arch Pharmacol. 355:1997;R41.
100. G-nitro L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res. 72:1993;387-395.